$70.84
0.741.06%
At Close: -
$65.50
-5.34-7.54%
After Hours: Jun 26, 7:00 AM EDT
15 minutes delayed
Invesco Biotechnology & Genome ETF (ARCA: PBE)
Ticker | Name | Share % | |
---|---|---|---|
BMRN | Biomarin Pharmaceutical Inc. | 5.39% | |
REGN | Regeneron Pharmaceuticals, Inc. | 5.27% | |
GILD | Gilead Sciences Inc | 5.23% | |
INCY | Incyte | 5.16% | |
VRTX | Vertex Pharmaceuticals Inc | 5.11% | |
AMGN | Amgen Inc. | 5.07% | |
ILMN | Illumina Inc | 4.97% | |
NBIX | Neurocrine Biosciences Inc | 4.78% | |
IONS | Ionis Pharmaceuticals Inc | 3.37% | |
HALO | Halozyme Therapeutics Inc | 3.23% |
The PBE ETF is currently trading at $65.50, which represents a -6.56% change. Over the past 52 weeks, the ETF has traded as high as $70.70 and as low as $52.47.
The expense ratio of PBE is NA%. This represents the annual fee that all funds or ETFs charge their shareholders.
The total Assets Under Management (AUM) for PBE is 271.00M. This represents the total market value of the assets managed by the ETF.
PBE follows a Mid Cap Growth investment style.
The top holdings of PBE include: BMRN (5.39%), REGN (5.27%), GILD (5.23%), INCY (5.16%), VRTX (5.11%). These represent the largest positions in the ETF's portfolio.
Average daily volume data for PBE is currently not available.